(BIO) Bio-Rad Laboratories - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 7.516m USD | Total Return: 22.1% in 12m

Instruments, Reagents, Test Kits, Software, Controls
Total Rating 43
Safety 81
Buy Signal -0.19
Medical Devices -5.6
Life Sciences Tools & Services +15.3
Market Cap: 7,516m
Avg Trading Vol: 75.8M USD
ATR: 3.03%
Peers RS (IBD): 61.7
Risk 5d forecast
Volatility37.8%
Rel. Tail Risk-9.43%
Reward TTM
Sharpe Ratio0.42
Alpha0.85
Character TTM
Beta0.826
Beta Downside1.282
Drawdowns 3y
Max DD55.48%
CAGR/Max DD-0.28
EPS (Earnings per Share) EPS (Earnings per Share) of BIO over the last years for every Quarter: "2021-03": 5.21, "2021-06": 3.54, "2021-09": 3.71, "2021-12": 3.21, "2022-03": 4.94, "2022-06": 3.38, "2022-09": 2.6, "2022-12": 3.31, "2023-03": 3.34, "2023-06": 3, "2023-09": 2.33, "2023-12": 3.1, "2024-03": 2.29, "2024-06": 3.11, "2024-09": 2.01, "2024-12": 2.9, "2025-03": 2.54, "2025-06": 2.61, "2025-09": 2.26, "2025-12": 2.51, "2026-03": 0,
EPS CAGR: -50.50%
EPS Trend: -55.9%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of BIO over the last years for every Quarter: 2021-03: 726.796, 2021-06: 715.931, 2021-09: 747.049, 2021-12: 732.769, 2022-03: 700.062, 2022-06: 691.099, 2022-09: 680.8, 2022-12: 730.288, 2023-03: 676.844, 2023-06: 681.11, 2023-09: 632.124, 2023-12: 681.184, 2024-03: 610.82, 2024-06: 638.476, 2024-09: 649.729, 2024-12: 667.475, 2025-03: 585.4, 2025-06: 651.6, 2025-09: 653, 2025-12: 693.2, 2026-03: null,
Rev. CAGR: -0.26%
Rev. Trend: -47.8%
Last SUE: 0.50
Qual. Beats: 0
Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: BIO Bio-Rad Laboratories

Bio-Rad Laboratories (NYSE: BIO) designs, manufactures and distributes life-science research and clinical-diagnostic products worldwide, operating through two primary segments: Life Science, which supplies instruments, reagents and consumables for research, biopharma manufacturing and food safety; and Clinical Diagnostics, which provides test systems, kits and software for hospitals, reference labs and physician offices.

In FY 2025 the company reported $3.12 billion in revenue, a 7 % YoY increase driven largely by its Clinical Diagnostics line, which grew 10 % to $1.45 billion. Adjusted EPS reached $2.10 and operating margin expanded to 20 %, while cash flow from operations topped $400 million, supporting a $1.2 billion share-repurchase program.

Key sector tailwinds include accelerating biotech R&D spend-projected to rise above 8 % annually-fueling demand for Bio-Rad’s nucleic-acid and protein analysis tools, and an aging global population that is boosting the market for molecular and immuno-diagnostic testing, a core growth engine for its Clinical Diagnostics segment.

For a deeper dive into BIO’s valuation metrics, you might explore ValueRay’s analyst tools.

Headlines to Watch Out For
  • Life science research spending impacts instrument and reagent sales
  • Clinical diagnostics demand drives revenue growth
  • Competition from larger diagnostic companies pressures market share
  • Research and development costs affect profitability
  • Regulatory approvals are crucial for new product launches
Piotroski VR‑10 (Strict) 5.5
Net Income: 759.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.70 > 1.0
NWC/Revenue: 92.49% < 20% (prev 99.84%; Δ -7.35% < -1%)
CFO/TA 0.05 > 3% & CFO 532.2m > Net Income 759.9m
Net Debt (999.2m) to EBITDA (845.6m): 1.18 < 3
Current Ratio: 5.62 > 1.5 & < 3
Outstanding Shares: last quarter (27.0m) vs 12m ago -3.52% < -2%
Gross Margin: 51.87% > 18% (prev 0.54%; Δ 5.13k% > 0.5%)
Asset Turnover: 25.91% > 50% (prev 27.41%; Δ -1.50% > 0%)
Interest Coverage Ratio: 13.27 > 6 (EBITDA TTM 845.6m / Interest Expense TTM 49.0m)
Altman Z'' 7.13
A: 0.23 (Total Current Assets 2.91b - Total Current Liabilities 517.0m) / Total Assets 10.58b
B: 0.77 (Retained Earnings 8.18b / Total Assets 10.58b)
C: 0.07 (EBIT TTM 650.3m / Avg Total Assets 9.97b)
D: 2.56 (Book Value of Equity 7.99b / Total Liabilities 3.12b)
Altman-Z'' Score: 7.13 = AAA
Beneish M -2.88
DSRI: 1.04 (Receivables 472.5m/452.5m, Revenue 2.58b/2.57b)
GMI: 1.04 (GM 51.87% / 53.77%)
AQI: 1.09 (AQ_t 0.66 / AQ_t-1 0.60)
SGI: 1.01 (Revenue 2.58b / 2.57b)
TATA: 0.02 (NI 759.9m - CFO 532.2m) / TA 10.58b)
Beneish M-Score: -2.88 (Cap -4..+1) = A
What is the price of BIO shares? As of April 06, 2026, the stock is trading at USD 279.99 with a total of 253,647 shares traded.
Over the past week, the price has changed by +3.56%, over one month by +0.34%, over three months by -13.14% and over the past year by +22.05%.
Is BIO a buy, sell or hold? Bio-Rad Laboratories has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BIO.
  • StrongBuy: 2
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the BIO price?
Wallstreet Target Price 321.3 14.7%
Analysts Target Price 321.3 14.7%
BIO Fundamental Data Overview as of 02 April 2026
P/E Trailing = 9.995
P/E Forward = 27.5482
P/S = 2.9097
P/B = 1.0094
P/EG = 1.1905
Revenue TTM = 2.58b USD
EBIT TTM = 650.3m USD
EBITDA TTM = 845.6m USD
Long Term Debt = 1.20b USD (from longTermDebt, last quarter)
Short Term Debt = 37.9m USD (from shortTermDebt, last quarter)
Debt = 1.53b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 999.2m USD (from netDebt column, last quarter)
Enterprise Value = 8.52b USD (7.52b + Debt 1.53b - CCE 529.8m)
Interest Coverage Ratio = 13.27 (Ebit TTM 650.3m / Interest Expense TTM 49.0m)
EV/FCF = 22.74x (Enterprise Value 8.52b / FCF TTM 374.6m)
FCF Yield = 4.40% (FCF TTM 374.6m / Enterprise Value 8.52b)
FCF Margin = 14.50% (FCF TTM 374.6m / Revenue TTM 2.58b)
Net Margin = 29.42% (Net Income TTM 759.9m / Revenue TTM 2.58b)
Gross Margin = 51.87% ((Revenue TTM 2.58b - Cost of Revenue TTM 1.24b) / Revenue TTM)
Gross Margin QoQ = 49.80% (prev 52.59%)
Tobins Q-Ratio = 0.81 (Enterprise Value 8.52b / Total Assets 10.58b)
Interest Expense / Debt = 0.79% (Interest Expense 12.1m / Debt 1.53b)
Taxrate = 22.51% (209.2m / 929.2m)
NOPAT = 503.9m (EBIT 650.3m * (1 - 22.51%))
Current Ratio = 5.62 (Total Current Assets 2.91b / Total Current Liabilities 517.0m)
Debt / Equity = 0.21 (Debt 1.53b / totalStockholderEquity, last quarter 7.45b)
Debt / EBITDA = 1.18 (Net Debt 999.2m / EBITDA 845.6m)
Debt / FCF = 2.67 (Net Debt 999.2m / FCF TTM 374.6m)
Total Stockholder Equity = 7.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.62% (Net Income 759.9m / Total Assets 10.58b)
RoE = 10.86% (Net Income TTM 759.9m / Total Stockholder Equity 7.00b)
RoCE = 7.93% (EBIT 650.3m / Capital Employed (Equity 7.00b + L.T.Debt 1.20b))
RoIC = 6.14% (NOPAT 503.9m / Invested Capital 8.20b)
WACC = 7.49% (E(7.52b)/V(9.05b) * Re(8.89%) + D(1.53b)/V(9.05b) * Rd(0.79%) * (1-Tc(0.23)))
Discount Rate = 8.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.18%
[DCF] Terminal Value 83.28% ; FCFF base≈331.2m ; Y1≈408.6m ; Y5≈697.2m
[DCF] Fair Price = 565.0 (EV 13.39b - Net Debt 999.2m = Equity 12.39b / Shares 21.9m; r=7.49% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -55.93 | EPS CAGR: -50.50% | SUE: -4.0 | # QB: 0
Revenue Correlation: -47.83 | Revenue CAGR: -0.26% | SUE: 0.50 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.49 | Chg7d=-0.003 | Chg30d=-0.036 | Revisions Net=-4 | Analysts=3
EPS current Year (2026-12-31): EPS=10.22 | Chg7d=-0.011 | Chg30d=-0.055 | Revisions Net=-3 | Growth EPS=+3.0% | Growth Revenue=+1.6%
EPS next Year (2027-12-31): EPS=11.34 | Chg7d=+0.022 | Chg30d=-0.030 | Revisions Net=-1 | Growth EPS=+11.0% | Growth Revenue=+3.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -1.1% (Discount Rate 8.9% - Earnings Yield 10.0%)
[Growth] Growth Spread = +2.1% (Analyst 1.0% - Implied -1.1%)
External Resources
Dataroma Stockcircle